Selank

The calmer sibling of Semax in the same development tradition. Anxiety and asthenia are the usual claims. Evidence is regional and small; it is not a validated alternative to standard anxiolytics.

A tuftsin analog with a Pro-Gly-Pro extension. Proposed anxiolytic action via GABA-related and enkephalin-degrading enzyme effects, plus modest immune-modulating claims from the tuftsin parent.

Small clinical series in Russia for generalized anxiety and related states. No large, multi-site Western RCTs. Immunology claims rest on tuftsin biology more than on modern trial endpoints.

Used in Russia. Not FDA-approved. Research-chemical or import channel in the US.

Same development tradition as Semax: used in Russia, not FDA-approved, US research-chemical/import channel. Not among the July 2026 PCAC-recommended six.

Same four pathways as the Sourcing guide.

None in the US.

Intranasal anxiety-marketed sprays. Preservatives and dose vary.

Strand does not list vendors. See the grey market.

Generally described as well tolerated in originating studies. That is not the same as a modern safety database. Intranasal products vary in concentration and preservatives.

• No large Western RCTs.
• Not a substitute for standard anxiolytics with outcome data.
• Product quality of imported sprays is unknown.

• Seredenin et al.

  Anxiolytic tuftsin analog series from the Institute of Pharmacology.

• Evidence standard

  No FDA-reviewed anxiety indication; no large Western RCTs.